GammaDelta spins out Adaptate to focus on antibody therapies
As GammaDelta nears bringing its T cell therapies to the clinic, it’s spinning out Adaptate to focus on the development of its γδ antibody-based programs.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) has a time-limited option to acquire Adaptate Biotherapeutics Ltd. and has provided undisclosed funding, along with Abingworth. ...